Riccardi Niccolò, Del Puente Filippo, Taramasso Lucia, Di Biagio Antonio
1 Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
2 Infectious Diseases, Policlinico San Martino Hospital, Genoa, Italy.
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821657. doi: 10.1177/2325958218821657.
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor-based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.
基于非核苷类逆转录酶抑制剂加整合酶链转移抑制剂的双重疗法，对于有经验的人类免疫缺陷病毒感染患者而言，是一种颇具吸引力的简化治疗方案，即一种避免使用核苷类逆转录酶抑制剂的策略。因此，我们开展了一项为期24周的真实世界观察性研究，以评估7例既往接受过大量治疗的患者从拉替拉韦加依曲韦林转换为度鲁特韦加利匹韦林后的疗效和安全性。这种简化策略减轻了服药负担，并在既往基因分型时对利匹韦林无主要突变的经治患者中维持了病毒抑制。
